BR0306784A - Sequência de ácido nucléico isolada, constructo repórter, célula hospedeira compreendendo o mesmo, método de identificação de agentes que modulam a expressão de ingap, método para a modulação da expressão ingap, bem como uso de um fator que estimula uma expressão de ingap na fabricação de uma composição farmacêutica - Google Patents

Sequência de ácido nucléico isolada, constructo repórter, célula hospedeira compreendendo o mesmo, método de identificação de agentes que modulam a expressão de ingap, método para a modulação da expressão ingap, bem como uso de um fator que estimula uma expressão de ingap na fabricação de uma composição farmacêutica

Info

Publication number
BR0306784A
BR0306784A BR0306784-0A BR0306784A BR0306784A BR 0306784 A BR0306784 A BR 0306784A BR 0306784 A BR0306784 A BR 0306784A BR 0306784 A BR0306784 A BR 0306784A
Authority
BR
Brazil
Prior art keywords
expression
ingap expression
ingap
reporter construct
nucleic acid
Prior art date
Application number
BR0306784-0A
Other languages
English (en)
Inventor
David Taylor-Fishwick
Aaron I Vinik
Original Assignee
Gmp Endotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Endotherapeutics Inc filed Critical Gmp Endotherapeutics Inc
Publication of BR0306784A publication Critical patent/BR0306784A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4733—Acute pancreatitis-associated protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/474—Pancreatic thread protein; Reg protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"SEQuêNCIA DE áCIDO NUCLéICO ISOLADA, CONSTRUCTO REPóRTER, CéLULA HOSPEDEIRA COMPREENDENDO O MESMO, MéTODO DE IDENTIFICAçãO DE AGENTES QUE MODULAM A EXPRESSãO DE INGAP, MéTODO PARA A MODULAçãO DA EXPRESSãO INGAP, BEM COMO USO DE UM FATOR QUE ESTIMULA UMA EXPRESSãO DE INGAP NA FABRICAçãO DE UMA COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a um constructo repórter que contém a região reguladora 5<39> de INGAP de mamífero ou um fragmento da mesma, um elemento promotor mínimo de INGAP de mamífero ou um promotor heterólogo, e um gene repórter. O constructo repórter pode ser utilizado para a triagem de agentes que, isoladamente ou em combinação, regulam para cima ou regulam para baixo a expressão do gene repórter. Alternativamente, o constructo repórter pode ser utilizado para a triagem de agentes que se ligam à região reguladora 5<39> de INGAP do hamster, ou um fragmento da mesma.
BR0306784-0A 2002-01-11 2003-01-10 Sequência de ácido nucléico isolada, constructo repórter, célula hospedeira compreendendo o mesmo, método de identificação de agentes que modulam a expressão de ingap, método para a modulação da expressão ingap, bem como uso de um fator que estimula uma expressão de ingap na fabricação de uma composição farmacêutica BR0306784A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34689802P 2002-01-11 2002-01-11
US36107302P 2002-03-01 2002-03-01
US38831502P 2002-06-14 2002-06-14
PCT/US2003/000707 WO2003060096A2 (en) 2002-01-11 2003-01-10 Assay for the detection of factors that modulate the expression of ingap

Publications (1)

Publication Number Publication Date
BR0306784A true BR0306784A (pt) 2005-04-26

Family

ID=27407757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306784-0A BR0306784A (pt) 2002-01-11 2003-01-10 Sequência de ácido nucléico isolada, constructo repórter, célula hospedeira compreendendo o mesmo, método de identificação de agentes que modulam a expressão de ingap, método para a modulação da expressão ingap, bem como uso de um fator que estimula uma expressão de ingap na fabricação de uma composição farmacêutica

Country Status (13)

Country Link
US (3) US7355024B2 (pt)
EP (1) EP1463517A4 (pt)
JP (1) JP2005514930A (pt)
KR (2) KR20070043057A (pt)
CN (1) CN1615150A (pt)
BR (1) BR0306784A (pt)
CA (1) CA2470359A1 (pt)
IL (1) IL162493A0 (pt)
MA (1) MA27241A1 (pt)
MX (1) MXPA04006708A (pt)
NO (1) NO20043330L (pt)
PL (1) PL371485A1 (pt)
WO (1) WO2003060096A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103305457B (zh) * 2013-06-06 2015-07-08 浙江省医学科学院 一种体外扩增胰岛β细胞的方法
WO2017186121A1 (zh) * 2016-04-26 2017-11-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
CN110906869A (zh) * 2019-11-22 2020-03-24 深圳市太赫兹科技创新研究院有限公司 一种oct探头调节装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE494374T1 (de) 1995-02-22 2011-01-15 Eastern Virginia Med School Ingap-protein und dessen beteiligung an der neogenese pankreatischer inselzellen
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US6090620A (en) * 1995-12-29 2000-07-18 University Of Washington Genes and gene products related to Werner's syndrome

Also Published As

Publication number Publication date
PL371485A1 (en) 2005-06-13
JP2005514930A (ja) 2005-05-26
KR20070043057A (ko) 2007-04-24
AU2003202273A1 (en) 2003-07-30
US7355024B2 (en) 2008-04-08
US20030207301A1 (en) 2003-11-06
WO2003060096A3 (en) 2003-12-04
NO20043330L (no) 2004-10-05
CN1615150A (zh) 2005-05-11
IL162493A0 (en) 2005-11-20
EP1463517A4 (en) 2006-01-04
KR100766759B1 (ko) 2007-10-15
KR20040072700A (ko) 2004-08-18
US20120058078A1 (en) 2012-03-08
WO2003060096A2 (en) 2003-07-24
MXPA04006708A (es) 2005-03-31
US20090156458A1 (en) 2009-06-18
MA27241A1 (fr) 2005-03-01
CA2470359A1 (en) 2003-07-24
EP1463517A2 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
Swenson et al. The clam embryo protein cyclin A induces entry into M phase and the resumption of meiosis in Xenopus oocytes
Valdez et al. Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients
Zhang et al. The nucleosome remodeling and deacetylase complex NuRD is built from preformed catalytically active sub-modules
Shoji et al. Cytochalasin D acts as an inhibitor of the actin–cofilin interaction
Sivan et al. Ribosomal slowdown mediates translational arrest during cellular division
Wu et al. Vitamin C enhances Nanog expression via activation of the JAK/STAT signaling pathway
Janssen et al. A major substrate of maturation promoting factor identified as elongation factor 1 beta gamma delta in Xenopus laevis
ES2139552T1 (es) Moduladores de la transcripcion regulado por tetraciclinas.
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
Steffens et al. The BEACH domain protein SPIRRIG is essential for Arabidopsis salt stress tolerance and functions as a regulator of transcript stabilization and localization
DE69938600D1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
Enríquez et al. The synthesis of mRNA in isolated mitochondria can be maintained for several hours and is inhibited by high levels of ATP
Marijan et al. Stress‐specific aggregation of proteins in the amyloid bodies
Duncan et al. Regulation of initiation factors during translational repression caused by serum depletion. Abundance, synthesis, and turnover rates.
BRPI0813913A8 (pt) Molécula de ácido nucleico, sequência de ácido nucleico recombinante, célula hospedeira, métodos para produzir fsh humano recombinante, e para produzir a célula hospedeira, e, uso de uma sequência de ácido nucleico.
BR112023020167A2 (pt) Fusões agente-ligante de ligação biespecífica para a degradação de proteínas alvo
BRPI0519344A2 (pt) promotor induzÍvel por l-lisina
Ratushnyy et al. Expansion of adipose tissue‐derived stromal cells at “physiologic” hypoxia attenuates replicative senescence
Webb et al. 1-(N-alkylamino)-11-(N-ethylamino)-4, 8-diazaundecanes: simple synthetic polyamine analogues that differentially alter tubulin polymerization
Elliott et al. How does Tra2β protein regulate tissue-specific RNA splicing?
BR0306784A (pt) Sequência de ácido nucléico isolada, constructo repórter, célula hospedeira compreendendo o mesmo, método de identificação de agentes que modulam a expressão de ingap, método para a modulação da expressão ingap, bem como uso de um fator que estimula uma expressão de ingap na fabricação de uma composição farmacêutica
Hannon et al. Control of RNA polymerase binding to chromatin by variations in linker histone composition
ATE532868T1 (de) Apoptose induzierende positivkontrolle für expressionsmodulationsexperimente
Fiscus et al. Nitric oxide and cyclic GMP as pro‐and anti‐apoptotic agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O, 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010.